Volker Wiebking

Medicine · Health Sciences

17h-index2.3kcitations51works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(18), Virus-based gene therapy research(10), CRISPR and Genetic Engineering(10), Lymphoma Diagnosis and Treatment(7), Biosimilars and Bioanalytical Methods(6)

Publications51 total

Population Pharmacokinetics of Subcutaneous Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
2026Open Access
Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study
Blood·2025Open Access
POSTER: IBCL-482 Fixed-Duration Subcutaneous Mosunetuzumab (Mosun SC) Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome (CRS), and Non-Inferior Exposure Compared With Intravenous Administration in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Primary Analysis of a Pivotal Phase 2 Study
Clinical Lymphoma Myeloma & Leukemia·2025
IBCL-482: Fixed-Duration Subcutaneous Mosunetuzumab (Mosun SC) Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome (CRS), and Non-Inferior Exposure Compared With Intravenous Administration in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Primary Analysis of a Pivotal Phase 2 Study
Clinical Lymphoma Myeloma & Leukemia·2025
Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
Nature·2025· 31 citedOpen Access
576 | FIXED‐DURATION SUBCUTANEOUS MOSUNETUZUMAB HAD SIMILAR EFFICACY BUT LOWER CYTOKINE RELEASE SYNDROME RISK VERSUS EPCORITAMAB IN 3L+ FOLLICULAR LYMPHOMA: AN INDIRECT COMPARISON
Hematological Oncology·2025Open Access
237 | FIXED‐DURATION SUBCUTANEOUS MOSUNETUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA WITH HIGH‐RISK FEATURES: PIVOTAL PHASE II STUDY UPDATE
Hematological Oncology·2025Open Access
CRISPR engineering of armored CAR T cells enables tumor restricted payload delivery with enhanced efficacy and safety
2025Open Access
TET2 regulates early and late transitions in exhausted CD8 <sup>+</sup> T cell differentiation and limits CAR T cell function
Science Advances·2024· 18 citedOpen Access
Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
Blood·2024· 6 citedOpen Access
TET2 regulates early and late transitions in exhausted CD8 <sup>+</sup> T-cell differentiation and limits CAR T-cell function
2024Open Access
Data from Tuning the Antigen Density Requirement for CAR T-cell Activity
2023Open Access
Data from Tuning the Antigen Density Requirement for CAR T-cell Activity
2023Open Access
Supplementary Data from Tuning the Antigen Density Requirement for CAR T-cell Activity
2023Open Access
Supplementary Data from Tuning the Antigen Density Requirement for CAR T-cell Activity
2023Open Access
Data from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
Data from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Matthew H. Porteus(22), Anna P. Hnatiuk(9), Mallesh Pandrala(9), Arpit Dheeraj(9), Dries Feyen(9), Prashila Amatya(9), Isabel Morgado(9), Sanjay V. Malhotra(9), Mark Mercola(9), Irene Schmid(8), Arne A.N. Bruyneel(8), Michelle M. Vu(8), Ronglih Liao(8), Ravindra Majeti(8), Ciaran M. Lee(7), Gang Bao(7), Evan W. Weber(7), Michael H. Albert(7), Dhanir Tailor(7), Ricardo Serrano(7)